These drugs target some of the most pressing cancer types, including multiple myeloma, breast cancer, and bladder cancer ...

Retifanlimab-dlwr (Zynyz) has been granted approval from the FDA for treatment of locally recurrent or metastatic squamous ...

The FDA has approved Zynyz as a first-line treatment in combination with chemo and as a single-agent following progression in ...

With significant survival improvements seen, the FDA has granted approval to retifanlimab for the first-line treatment of ...

Efti plus Keytruda and chemo achieved a 61% response rate in first-line advanced non-squamous non–small cell lung cancer, ...

Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | ...

Biotech investors are preparing for what may be the most important clinical trial readout for them this summer.

This drugmaker achieved a milestone - its first quarterly profit. But the stock is down despite the good tidings.

Amplia Therapeutics and Immutep have released clinical trial results that promise more effective treatments for pancreatic and lung cancers ...

IO Biotech was named to Fast Company’s World’s Most Innovative Companies of 2025 list for its potentially game-changing approach to immune-modulatory cancer vaccines, earning its place on the coveted ...

GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a ...

Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, align with recent bad news for this once-promising ...